Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas

被引:114
作者
Sung, T
Miller, DC
Hayes, RL
Alonso, M
Yee, H
Newcomb, EW [1 ]
机构
[1] NYU, Sch Med, Dept Pathol, Div Neuropathol, New York, NY 10016 USA
[2] Staten Isl Univ Hosp, Dept Med, Nalitt Inst Canc, Staten Isl, NY USA
[3] Kaplan Comprehens Canc Ctr, New York, NY USA
关键词
D O I
10.1111/j.1750-3639.2000.tb00258.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Classification of high grade astrocytomas of children into genetic subtypes similar to the adult remains to be defined. Here we report an extensive characterization of 29 high grade pediatric astrocytomas, 7 WHO grade III and 22 WHO grade IV, for genetic alterations frequently observed in high grade adult astrocytomas occurring in either the p53/MDM2/p14(ARF) Or Rb/CDK4/p16(INK4a) tumor suppressor pathways. In addition, we have assessed the contribution of EGFR overexpression and amplification and LOH for chromosome 10, two genetic alterations commonly associated with the development of de novo adult glioblastoma for their roles in the development of de novo astrocytomas of childhood. Our results suggest two major differences in the genetic pathway(s) leading to the formation of de novo high grade astrocytomas in children compared with those of the adult. Our findings show preferential inactivation of the p53 tumor suppressor pathway in >95% of pediatric astrocytomas versus inactivation of the Rb tumor suppressor pathway in <25% of the same tumors. In addition, de novo high grade pediatric astrocytomas lack amplification of the EGFR gene compared with EGFR amplification in one-third of adult glioblastomas. Since drug treatments and gene therapy strategies exploit specific genetic alterations in tumor cells, our findings have important implications for the future development of treatments for high grade pediatric astrocytomas.
引用
收藏
页码:249 / 259
页数:11
相关论文
共 54 条
[1]  
BASWIGA J, 1998, CANCER RES, V58, P2825
[2]   Amplification and overexpression of MDM2 in primary (de novo) glioblastomas [J].
Biernat, W ;
Kleihues, P ;
Yonekawa, Y ;
Ohgaki, H .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (02) :180-185
[3]   Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas [J].
Biernat, W ;
Tohma, Y ;
Yonekawa, Y ;
Kleihues, P ;
Ohgaki, H .
ACTA NEUROPATHOLOGICA, 1997, 94 (04) :303-309
[4]  
Boström J, 1998, CANCER RES, V58, P29
[5]   Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas [J].
Burns, KL ;
Ueki, K ;
Jhung, SL ;
Koh, J ;
Louis, DN .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (02) :122-130
[6]   Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors [J].
Cheng, Y ;
Ng, HK ;
Ding, M ;
Zhang, SF ;
Pang, JCS ;
Lo, KW .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1999, 58 (02) :120-128
[7]   Genetic alterations in pediatric high-grade astrocytomas [J].
Cheng, Y ;
Ng, HK ;
Zhang, SF ;
Ding, M ;
Pang, JCS ;
Zheng, J ;
Poon, WS .
HUMAN PATHOLOGY, 1999, 30 (11) :1284-1290
[8]   GLIOBLASTOMA MULTIFORME IN CHILDREN [J].
DOHRMANN, GJ ;
FARWELL, JR ;
FLANNERY, JT .
JOURNAL OF NEUROSURGERY, 1976, 44 (04) :442-448
[9]   PTEN mutations in gliomas and glioneuronal tumors [J].
Duerr, EM ;
Rollbrocker, B ;
Hayashi, Y ;
Peters, N ;
Meyer-Puttlitz, B ;
Louis, DN ;
Schramm, J ;
Wiestler, OD ;
Parsons, R ;
Eng, C ;
von Deimling, A .
ONCOGENE, 1998, 16 (17) :2259-2264
[10]   P53 GENE-MUTATIONS IN PEDIATRIC BRAIN-TUMORS [J].
FELIX, CA ;
SLAVC, I ;
DUNN, M ;
STRAUSS, EA ;
PHILLIPS, PC ;
RORKE, LB ;
SUTTON, L ;
BUNIN, GR ;
BIEGEL, JA .
MEDICAL AND PEDIATRIC ONCOLOGY, 1995, 25 (06) :431-436